SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 8, 2003
INYX, INC.
(Exact name of registrant as specified in its charter)
Nevada 333-83152 75-2870720
- ------ --------- ----------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
801 Brickell Avenue, Ninth Floor, Miami, Florida 33131
------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (305) 789-6649
Item 9. Regulation FD Disclosure
------------------------
Information required by Item 12 is being provided under this Item 9
pursuant to the Securities and Exchange Commission's (the "SEC") interim filing
guidance set forth in Release Nos. 33-8216 and 34-47583.
On October 8, 2003, Inyx , Inc. (the "Company") issued a press release
announcing preliminary sales numbers for its third fiscal 2003 quarter ended
September 30, 2003. A copy of this press release follows the signatures below.
This information is being furnished, and shall not be deemed to be
"filed," with the SEC. The information is this Current Report on Form 8-K shall
not be incorporated by reference into any filing of the registrant with the SEC,
whether made before or after the date hereof, regardless of any general
incorporation language in such filings.
Item 12: Results of Operations and Financial Condition
---------------------------------------------
See Item 9 above.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INYX, INC.
By: /s/ Jack Kachkar
-----------------------------
Jack Kachkar, Chairman
Dated: October 8, 2003
Press Release of Inyx, Inc. dated October 8, 2003
INyX
================================================================================
PRESS RELEASE - FOR IMMEDIATE RELEASE
INYX REPORTS PRELIMINARY THIRD-QUARTER REVENUES;
SALES NOW AT $23 MILLION-PLUS ANNUAL RATE AND COMPANY EXPECTS
NET INCOME OF $2 MILLION IN 2004
MIAMI - OCTOBER 8, 2003 -- Inyx, Inc. (OTC BB: IYXI), a development and contract
manufacturer of specialized drug delivery pharmaceutical products, announced
today that the company's revenues in the third quarter ended September 30, 2003
amounted to approximately $3.1 million. The company will file detailed
third-quarter results in November.
Inyx also reported that, based on recently received new long-term development
and manufacturing contracts, revenues are now at about a $2 million monthly
rate. The company expects 2003 fourth-quarter sales to total approximately $5
million. (Inyx's operating facilities are in the United Kingdom and are
traditionally closed for two weeks at year-end for the holiday season).
Moreover, Inyx stated that it expects revenues in 2004 to reach in excess of $23
million and to achieve net income of approximately $2 million, based on current
customer-order and product-approval schedules.
Jack Kachkar, M.D., chairman of Inyx, said, "We are pleased with the rapid
corporate and business development of our company, which went public through a
reverse merger that was completed on April 28, 2003." Dr. Kachkar noted that
"the revenues and earnings currently forecasted do not include development of
Inyx's own products."
"The next phase of Inyx's evolution is to utilize our company's aerosol drug
delivery technology to develop our own proprietary products in conjunction with
a number of our customers. This will commence in 2004, as we already have
strategic relationships in place with key clients for business-development
support and to utilize their pharmaceutical sales forces for the marketing of
Inyx proprietary products in the dermatology, respiratory and allergy markets,"
explained the company chairman.
About Inyx
Inyx, Inc. is a development and contract manufacturer of specialized drug
delivery pharmaceutical products. The company's operations are conducted through
its subsidiary, INyX Pharma Limited, with a focus on niche products and
technologies for the treatment of respiratory, allergy, dermatological and
topical conditions. INyX Pharma's client base comprises blue-chip ethical
pharmaceutical companies, branded generic firms and biotechnology groups. INyX
Pharma manufactures for a majority of global markets including North America,
Europe, Latin America and the Middle East. Inyx, Inc. is headquartered in Miami,
Florida, with INyX Pharma's R&D and production facilities in Runcorn, near
Manchester, England.
Safe Harbor
Statements about the Company's future expectations, including future revenues
and earnings, and all other statements in this press release other than
historical facts, are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of
1934, and as that term is defined in the Private Securities Litigation Reform
Act of 1995. The Company intends that such forward-looking statements be subject
to the safe harbors created thereby. Since these statements involve risks and
uncertainties and are subject to change at any time, the Company's actual
results could differ materially from expected results.
For more information, please contact:
Truc N. Nguyen, VP Media Relations
Stern & Co.
212-888-0044
tnguyen@sternco.com